Serum adiponectin levels have been positively associated with insulin sensitivity and are decreased in type 2 diabetes (T2D) and obesity. Genetic and environmental factors influence serum adiponectin and may contribute to risk of metabolic syndrome and T2D. Therefore, we investigated the effect of ADIPOQ single-nucleotide polymorphisms (SNPs), −11377C>G and −11391G>A, on metabolic-related traits, and their modulation by dietary fat in white Americans. Data were collected from 1,083 subjects participating in the Genetics of Lipid Lowering Drugs and Diet Network study. Mean serum adiponectin concentration was higher for carriers of the −11391A allele (P = 0.001) but lower for the −11377G allele carriers (P = 0.017). Moreover, we found a significant association with obesity traits for the −11391G>A SNP. Carriers of the −11391A allele had significantly lower weight (P = 0.029), BMI (P = 0.019), waist (P = 0.003), and hip circumferences (P = 0.004) compared to noncarriers. Interestingly, the associations of the −11391G>A with BMI and obesity risk were modified by monounsaturated fatty acids (MUFAs) intake (P-interaction = 0.021 and 0.034 for BMI and obesity risk, respectively). In subjects with MUFA intake above the median (≥13% of energy intake), −11391A carriers had lower BMI (27.1 kg/m 2 for GA+AA vs. 29.1 kg/m 2 for GG, P = 0.002) and decreased obesity risk (odds ratio for −11391A = 0.52, 95% confidence interval (CI); 0.28-0.96; P = 0.031). However, we did not detect genotype-related differences for BMI or obesity in subjects with MUFA intake <13%. Our findings support a significant association between the −11391G>A SNPs and obesity-related traits and the potential to moderate such effects using dietary modification.
Adiponectin, an abundant adipocyte-derived protein, has been reported to protect against atherosclerosis through its antidiabetic and anti-inflammatory properties (1, 2) . Conversely, hypoadiponectinemia has been consistently observed in association with type 2 diabetes (T2D), coronary artery disease, and obesity (3) (4) (5) (6) . Moreover, adiponectin concentrations negatively correlated with triglyceride and positively with high-density lipoprotein cholesterol and low-density lipoprotein particle size (7) . Although the negative association between serum adiponectin and fasting triglyceride was independent of body fat mass and insulin sensitivity (8) , these phenotypes are not independent of one another but metabolically linked as clinical measures of obesity.
Serum adiponectin concentrations are highly heritable (~50%) and are linked to the ADIPOQ locus on chromosome 3q27 (refs. 9-13) , where a susceptibility locus for T2D (14, 15) and the metabolic syndrome (16) has been mapped. The four most commonly reported ADIPOQ single-nucleotide polymorphisms (SNPs) are rs17300539 (−11391G>A) and rs266729 (−11377C>G) in the promoter region and rs2241766 (45T>G) and rs1501299 (276G>T) in exon 2 and intron 2, respectively. These ADIPOQ SNPs have been associated with insulin resistance and obesity traits in some but not all studies (17, 18) . For instance, the ADIPOQ +45G allele was found to be associated with a higher risk of obesity and insulin resistance in a German population (19) (20, 21) . Lack of consistency has also been observed for the ADIPOQ 276G>T polymorphism in which the increased risk of obesity and insulin resistance was associated with the 276T allele among Italians (22) but with 276G allele among Greek women (23) . The different ethnicity and potential gene environment interactions may explain the lack of consistency in the quoted studies. Two promoter SNPs at the ADIPOQ locus, −11391G >A, and −11377C>G, have been shown to alter the plasma adiponectin concentrations and consequently affect the risk of T2D in French population (12) . In addition, the −11377C allele also contributed to obesity risk in T2D within a Swedish population (24) . In vitro studies further support the functionality of the −11391G>A SNP, demonstrating that the A allele significantly increases transcriptional activity and plasma adiponectin concentrations compared to the G allele (25) . In the current study, we focused on those promoter SNPs guided by previous in vitro information regarding their potential functionality.
It is well accepted that high-energy-dense and high-fat diets are positively associated with obesity. In addition, the quality of diet, in particular the types of fatty acids, could contribute to obesity and insulin resistance. Saturated fatty acids worsen insulin resistance, while monounsaturated fatty acids (MUFAs) and polyunsaturated fatty acids (PUFAs) improve insulin sensitivity (26) . Moreover, MUFA may lower the risk of obesity (27) . In this regard, weight reduction by hypocaloric Mediterranean-style diets and increased physical activity is associated with increased in plasma adiponectin concentrations as well as improved insulin sensitivity (28) .
Studies in animal models have shown that dietary fatty acids influence plasma adiponectin and ADIPOQ expression in rodents. A diet rich in n-3 PUFAs increased adiponectin concentrations and upregulated adipocyte (29-31) whereas saturated fat downregulated ADIPOQ expression (32, 33) .
We hypothesized that genetic variability, dietary fatty acids, and their interactions may modulate plasma adiponectin and contribute to risk for T2D, metabolic syndrome, and cardiovascular disease. Therefore, our objectives were to examine the association between the reportedly functional SNPs at ADIPOQ locus (−11377C>G and −11391G>A) and obesityrelated traits, and its modification by dietary fat in a wellcharacterized US white population.
Methods and Procedures subjects and study design
The study subjects consisted of 1,083 subjects (515 men and 568 women), aged 17-92 years, who participated in the Genetics of Lipid Lowering Drugs and Diet Network study and for whom complete and consistent dietary record are available (34) . The majority of participants were re-recruited from the three-generational pedigrees of two National Heart, Lung, and Blood Institute Family Heart Study field centers (Minneapolis, MN and Salt Lake City, UT) (35) . Detailed design and methodology of the Genetics of Lipid Lowering Drugs and Diet Network study has been described (34, 36) . Nearly all individuals were of European ancestry. Briefly, exclusion criteria were recent history (6 months) of myocardial infarction; history of liver, kidney, pancreas, or gall bladder disease; history of malabsorption of nutrients; current use of insulin; abnormal renal or hepatic function; and pregnancy or nursing in women. Individuals who reported current use of lipid-lowering drugs or dietary supplements known to influence lipids were required to consult their physician for approval to discontinue these lipid-lowering agents for 4 weeks before study participation. The protocol was approved by the Institutional Review Boards at the University of Alabama, the University of Minnesota, the University of Utah, and Tufts University. Written informed consent was obtained from all participants.
dietary and lifestyle assessment Habitual dietary intake was estimated using the Dietary history questionnaire, a cognitively based food-frequency questionnaire, developed by the National Cancer Institute (available online at http://riskfactor. cancer.gov/DHQ/). The ability to assess dietary intake has been validated, primarily in white US subjects and the average correlation coefficient between the dietary history questionnaire and four 24-h dietary recalls was 0. 62 (ref. 37) . Intake of total fat, saturated fatty acids, MUFAs, and PUFAs, including n-3 and n-6 PUFAs, were presented as percentage of total daily energy intake. We grouped the dietary intake of α-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid, and docosapentaenoic acid as n-3 PUFA. Linoleic acid and arachidonic acid were combined as n-6 PUFA. Self-reported physical activity based on types and durations of activities over 24 h, alcohol consumption, smoking, and current drug or hormonal use were described. Physical activity was calculated as metabolic-equivalent task hours. Alcohol consumption was described in amount of alcohol in gram per day. Smoking status was classified in three categories: current, former, and never smoking.
anthropometric measurement Anthropometric data including height, weight, and waist and hip circumferences were measured using a standard technique: height without shoes by a stadiometer, weight in light clothes by a beam balance, waist circumference over the unclothed abdomen at the umbilicus in the end of a normal expiration, and hip circumference at a maximal diameter by a nonstretchable standard tape. BMI was calculated by dividing the weight in kilograms by height in meters squared. We defined obesity as the BMI ≥30 kg/m 2 (38) Biochemical analyses Venous blood was obtained after an overnight fast, and all plasma samples were analyzed together at the end of the study. . Standard procedures of measurement of inflammatory markers; serum tumor necrosis factor-α, interleukin-6, and highly sensitive C-reactive protein have been described previously (40) .
dna isolation and ADIPOQ genotyping Genomic DNA was isolated from peripheral blood leukocytes using an AUTOPURE LS (Gentra Systems, Minneapolis, MN). Two promoter SNPs at ADIPOQ (rs17300539, −11391G>A; rs266729, −11377C>G) were genotyped by using a Taqman assay with allele-specific probes on articles genetics the ABIPrism 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA) (41) according to standardized laboratory protocols.
statistical analysis
Statistical analyses were carried out using SAS for Windows version 9.1.3 (SAS Institute, Cary, NC). Continuous variables were tested for normal distribution, and logarithmic transformations were applied to triglyceride, BMI, glucose, insulin, HOMA-R, adiponectin, tumor necrosis factor-α, interleukin-6, and highly sensitive C-reactive protein. Data for those variables are presented as back-transformed geometric means and 95% confidence intervals (CIs). Pearson's χ 2 and Fisher's exact tests were also used in unrelated subjects to test ADIPOQ genotypes for departure from Hardy-Weinberg equilibrium. We used the generalized estimating equation (42) linear and logistic regression with exchangeable correlation structure to adjust for the correlated observations due to familial relationship. For binary outcomes, the presented results (odds ratio and 95% CI) were the exponentiated β coefficient and 95% CI, which were computed at natural log scale. Analyses were performed for the whole sample, as well as for men and women separately, to verify the homogeneity of genetic effect among men and women. To determine the interaction between ADIPOQ SNPs and dietary fat intake, median levels of different fat intakes in this population were used as the cut point to dichotomize the corresponding variables. Interactions between SNPs and dietary fat intake (as dichotomous) were tested in the multivariate interaction model. Covariates included age, gender, BMI, smoking, alcohol consumption, physical activity expressed as metabolic-equivalent task hours, diabetes status, hormone treatment, total energy intake, and percentage of carbohydrate and protein intake. To address the potential issue of multiple comparisons, we calculated the false-discovery rate (FDR) for each P value of <0.05 by using the method of Benjamini and Hochberg (43) . The FDR is the expected proportion of false-positive results incurred when a particular test result is called significant. The pair-wise linkage disequilibrium between SNPs was estimated as correlation coefficient using the Helix Tree software package (Golden Helix, Bozeman, MT). A two-tailed P value of <0.05 was considered as statistically significant.
Bioinformatics analysis
Analysis of the genomic DNA sequence segment centered on the promoter variation at ADIPOQ was conducted with MAPPER (44) to identify potential transcription factor binding sites.
results
Characteristics of the study participants are listed in Table 1 . Genotype distributions did not deviate from Hardy-Weinberg expectation (P > 0.05) and minor allele frequencies of the ADIPOQ -11391G>A and −11377C>G were 0.07 and 0.25, respectively. The linkage disequilibrium between 2 SNPs was low (r 2 = 0.16), suggesting these SNPs are located on different haplotypes. We constructed haplotypes including both promoter SNPs using Helix tree; however, haplotype analysis did not provide information beyond that revealed by each SNP separately (data not presented). Therefore, we present the results of individual ADIPOQ polymorphisms. No significant interactions between genotype and gender for any of the main outcomes were observed, and we performed gender-adjusted analysis in all subjects combined. A dominant model was a better fit for these SNPs concerning the obesity traits; therefore, we combined heterozygous with homozygous for the minor allele. The two promoter SNPs were significantly associated with serum adiponectin concentrations in both crude and multivariate adjusted model (adjusted for age, gender, family relationship, smoking, alcohol consumption, physical activity, hormone, and diabetes status). Higher adiponectin levels were associated with the minor allele A of the −11391 G>A SNP (P = 0.0001), whereas the minor allele G of the −11377C>G was associated with a lower adiponectin concentrations (P = 0.027). Moreover, carriers of the −11391A allele had significantly lower weight (84.0 ± 1.6 kg vs. 86.8 ± 1.3 kg, P = 0.029), waist (97.3 ± 1.3 cm vs. 100.5 ± 1.1 cm, P = 0.002), and hip circumferences Genotyping study was successfully obtained in 509 men and 564 women for −11391G>A and 510 men and 562 women for −11377C>G. articles genetics individuals. Consistent with these findings, we found decreased insulin resistance, as determined by lower fasting insulin (P = 0.013) and HOMA-R (P = 0.009) in carriers of the minor allele. However, the significant difference of insulin resistance parameters across genotypes disappeared after adjusting for BMI ( Table 2) . None of these significant associations were observed for the −11377C>G SNP. We did not find significant associations between the two promoter polymorphisms and inflammation biomarkers, with the exception of a borderline significant association between the minor −11377G allele and higher tumor necrosis factor-α levels (P = 0.040) ( Table 2) .
Next, we examined the interaction between ADIPOQ SNPs and dietary fat in modifying adiposity and insulin resistance. We dichotomized the percentage of intakes for total fat (35%), saturated fatty acid (12%), MUFA (13%), PUFA (7%), n-3 PUFA (0.7%), and n-6 PUFA (7%) according to their respective medians. The −11391A allele was associated with lower BMI (27.5 vs. 29.0 kg/m², P = 0.019) only in subjects consuming fat ≥35% of total energy. When specific fatty acids were tested, the significantly lower BMI in A-allele carriers was found in the group of high MUFAs (P = 0.002) and n-3 PUFAs (P = 0.025), whereas BMI was not significantly different between −11391A and GG homozygotes among subjects with low fat (P = 0.878), MUFA (P = 0.902), and n-3 PUFA (P = 0.901) intake. Although a similar direction of effect on BMI was observed, only the interaction between ADIPOQ −11391G>A and MUFA interaction showed significant level (P = 0.021, Table 3 ). However, no statistically significant interactions were observed between ADIPOQ −11391G>A and saturated fatty acid and PUFA intake in relation to BMI. After controlling for multiple test comparisons by an FDR method, the A-allele carriers still had significantly lower BMI (P = 0.028) only in the group of high MUFAs. However, the interaction between the gene and MUFA did not reach statistically significant value (P = 0.147) after correction of multiple testing. No gene-diet interaction on BMI was observed for the ADIPOQ −11377C>G (P-interaction = 0.277). Neither −11391G>A nor −11377C>G SNPs showed significant interactions with dietary fat intake in relation to waist circumference or HOMA-R (data not presented).
We then employed logistic regression to test the effect of these ADIPOQ SNPs and dietary fat interaction on the risk of obesity. We found a significant interaction between the −11391G>A polymorphism and MUFA intake as categorical variable on the risk of obesity (P-interaction = 0.034) in a multivariate adjusted model ( Table 4) . At low MUFA intake (<13% of total energy), carriers of the −11391A allele had a nonsignificant higher risk of obesity (odds ratio = 1.30, 95% CI; 0.77-2.20; P = 0.347). In contrast, when the MUFA intake was high (≥13% of total energy), carriers of the −11391A allele had lower risk of obesity (odds ratio = 0.52, 95% CI; 0.28-0.96; P = 0.031) compared with GG subjects. No statistically significant interaction on obesity risk was observed for −11377C>G polymorphism (P-interaction = 0.553).
Computational analysis of the upstream region of the ADIPOQ gene with MAPPER, a tool designed to identify putative transcription factor-binding sites, revealed potential In this population of US whites, we provide evidence supporting a novel interaction between the ADIPOQ −11391G>A polymorphism and dietary MUFA intake affecting BMI and obesity risk. This gene-diet interaction was not observed for another promoter SNP (−11377C>G) of the same gene despite its association with plasma adiponectin concentrations. To address the potential issue of multiple comparisons, we calculated the FDR (43) to assess the significance of our results. Although, the interaction between ADIPOQ −11391 G>A, All dietary fat data were categorized by their median value of population. Data are adjusted geometric mean (95% confidence interval). MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid; TFA, trans fatty acid. * , **P for genotype and interaction term were obtained from the multivariate model after adjustment for age, gender, family relationship, smoking, alcohol consumption, physical activity, diabetes status, hormone treatment, total energy intake and percentage of carbohydrate and protein table 4 odds ratios (or) and 95% confidence interval (95% cI) for the obesity prevalence stratified by ADIPOQ −11391G>a and −11377c>G single-nucleotide polymorphisms and the median value of MuFa intake MUFA intake <13%
MUFA intake ≥13% P** for interaction OR P* 95% CI P* MUFA, monounsaturated fatty acid. * , **P value for the genotype and interaction term obtained in the corresponding logistic regression model after adjusting for age, gender, family relationships, tobacco smoking, alcohol consumption, physical activity, diabetes status, hormone, daily energy intake, and percentage of carbohydrate and protein in the corresponding strata of MUFA intake. articles genetics BMI, obesity, and MUFA reached statistical significance in unadjusted model, the observed interaction was not significant after FDR adjustment. Multiple testing challenges our interpretation of significance, exacerbated because there is no general consensus on how to best account for multiple comparisons (45, 46) . However, particularly noteworthy is that our nominally significant results are consistent with previous reports (12, (47) (48) (49) (50) , supporting an association between both promoter SNPs and serum adiponectin. The fact that this finding has been reported in several studies suggests that it is replicable, and likely represents a real biological relationship. The minor allele A at the ADIPOQ −11391G>A SNP was associated with higher plasma adiponectin concentrations (+23.7%) while the minor allele G at ADIPOQ −11377C>G SNP was associated with lower plasma adiponectin concentrations (-7.1%) compared to noncarriers. Despite these significant associations with plasma adiponectin concentrations, only the ADIPOQ −11391G>A SNP was significantly associated with a number of obesity-related traits including insulin resistance, weight, BMI, and waist and hip circumferences, suggesting different mechanisms driving the activity of these two promoter sites.
The major biological functions of adiponectin depend on the activation of adenosine-monophosphate-activated protein kinase primarily in skeletal muscles, which serves to increase fatty-acid oxidation and glucose uptake, thereby decreasing triglyceride content in muscle and liver, and improving insulin sensitivity. Adiponectin promotes adipocyte differentiation and fatty-acids uptake and maintains adipose tissue size and mass around set point (51) . For instance, in lean or weight loss state, smaller adipocytes secret more adiponectin to increasing adipocyte proliferation and lipid accumulation. On the other hand, in the obese or weight-gain states, the reduction in adiponectin secretion decreases fat accumulation, returning adipocytes to their baseline size. Of interest, administration of recombinant adiponectin in mice improved insulin resistance (52) and sustained weight loss without affecting food intake (53) . In the current findings, genetic variation at ADIPOQ −11391G>A was associated with plasma adiponectin concentrations, adiposity, and insulin resistance. The association between the −11391G>A and insulin resistance, however, was entirely accounted for by BMI, suggesting that the influence of this gene variant on glucose homeostasis may be dependent on body fatness. Our computational analysis of the upstream region of the ADIPOQ gene with MAPPER (44) revealed potential AP4-and CP2-binding sites for the ADIPOQ −11391A allele, whereas no transcription-binding site was predicted for the ADIPOQ −11377C>G. The association of the ADIPOQ −11391A with an increased adiponectin level may be accounted for by a higher transcription of ADIPOQ (25) . Several transcription factors regulate ADIPOQ expression, including peroxisome proliferation-activated receptor-γ, liver receptor homolog-1 (refs. 54,55) , CCAAT/enhancer-binding protein (C/EBP), nuclear factor-Y (56) and sterol-regulatoryelement-binding protein-1c (57) . However, there is no experimental data showing a direct relationship between AP-4 or CP-2 and ADIPOQ promoter activity or serum adiponectin.
Nevertheless, there is support for a relationship between C/ EBP and AP-4 through the E-box, upstream regulatory factor of the C/EBP gene, which was required for full activity of the C/EBP promoter. Purification of the E-box-binding protein during adipocyte differentiation led to the finding that USF-1 and USF-2 stimulates C/EBP expression, whereas AP-4 represses it (58) .
Previous studies on ADIPOQ polymorphisms have shown a wide range of inconsistent outcomes. Among Hispanics, the minor allele of −11391G>A was associated with significantly lower visceral fat, but no significant associations were observed for BMI, waist circumference, or waist-to-hip ratio (59) . Another study in French whites demonstrated that a GG haplotype, built using both promoter SNPs, that is, −11391G>A and −11377C>G, was associated with low-circulating adiponectin concentrations and with T2D, but these investigators did not find significant associations with fasting insulin or HOMA-R (12) . Moreover, they also demonstrated that the promoter haplotype was associated with the risk of T2D only in obese individuals (50) . Likewise, Buzzetti et al. failed to find an association with HOMA-R (47) in obese subjects, but statistically significant allele-related differences were observed with hyperinsulinemic-euglycemic clamp data. Only one study on Italian obese children found a significant association among the −11391A allele and higher serum adiponectin, lower fasting insulin, and HOMA-R (48). The potential reasons for the lack of consistency among studies are multiple. First, low statistical power resulting from a combination of small samples and low allele frequencies; second, different study designs, including subjects from different ethnic groups, ages, and health conditions; third, major methodological differences (clamp, fasting insulin, HOMA-R) used to assess insulin sensitivity and resistance; fourth, major differences in the approaches used for statistical analyses; and fifth, environmental factors surrounding the participants varied across studies.
The current study provides new insights in our understanding of the association among −11391G>A SNPs and obesity-related traits and its modulation by dietary fat, and provides some interesting leads toward more specific dietary recommendations in genetically susceptible individuals. In the highest 50th percentile of MUFA intake, carriers of the −11391A allele had lower BMI and risk of obesity compared with GG homozygotes, and the difference remained significant after FDR correction. On the other hand, in the lowest 50th percentile of MUFA intake, the −11391A allele was not associated with BMI or obesity risk. The reported interaction needs to be interpreted with caution and be maintained within the context of the specific circumstances of the population examined. In the American diet, the main source of MUFA is not olive oil (60) as in Mediterranean countries. It has been reported that a Mediterranean diet, high in dietary MUFA, and in combination with increased physical activity, was associated with weight loss, improved insulin sensitivity, and increased plasma adiponectin (28) . Moreover, in centrally obese insulin-resistant individuals, an isocaloric high-MUFA diet prevents central fat redistribution, postprandial decrease in adiponectin gene expression and insulin articles genetics resistance induced by high-carbohydrate (low-fat) diet (61) . A report in European obese women examined the ADIPOQ variants by nutrients interactions showing the possible interaction between −11377C>G and total fat intake in relation to obesity but not for −11391G>A SNP (62) . However, specific fatty acids were not explored and the sample size (549 subjects) did not have enough power to identify the gene nutrients interactions, especially for ADIPOQ −11391G>A with a low minor allele frequency (0.08). Peroxisome proliferation-activated receptor-γ is another plausible candidate gene that may influence the expression levels of ADIPOQ gene. Interactions between peroxisome proliferation-activated receptor-γ polymorphisms and MUFAs have been reported (63) . The findings in the Nurses' Health Study (63) for the peroxisome proliferation-activated receptor-γ Pro12Ala SNP showing associations between higher MUFA intake and lower BMI only in those subjects carrying the minor alleles at the respective loci are similar to those reported here for the ADIPOQ promoter SNP and support the important role of gene-diet interactions modulating complex traits.
In addition, it is important to note that the cross-sectional design of our study cannot provide evidence for the causality of this interaction and its mechanistic basis. Furthermore, our results representing the free-living US white population in Utah and Minnesota may not be generalized to other populations, in particular, those at high risk of the obesity and metabolic syndrome, such as Hispanic (64) and African-American populations (65) . Therefore, replication studies are needed to continue gaining further understanding of these interactions.
In conclusion, our findings support the current knowledge regarding significant associations between the promoter polymorphism at ADIPOQ (−11391G>A and −11377G>A) and serum adiponectin concentrations However, only ADIPOQ −11391G>A, which falls within the putative transcription binding site, was associated with obesity-related traits. Moreover, we found a possible interaction between this SNP and dietary MUFA modulating BMI and obesity risk. Although these findings need replication and more mechanistic understanding, they support the concept of personalized approaches to weight control and disease prevention. 
